Brief: Chugai Pharmaceutical announces results of Japanese phase III study of Alecensa

Chugai Ro Co

19/05/2016 02:01

May 18 (Reuters) - Chugai Pharmaceutical Co Ltd  
    * Announced results of Japanese phase III study of Alecensa 
in Alk fusion gene positive non-small cell lung cancer 
    * PFS hazard ratio of Alecensa arm to Crizotinib arm was 
0.34 and Alecensa demonstrated significantly prolonged PFS 
 
    Source text for Eikon:  ID:nBw66SnH4a  
 
 ((Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 
8780))